In the multicenter, randomized, placebo-controlled Q-SYMBIO trial, a daily CoQ10 intake of 300mg was found to significantly reduce the incidence of a major adverse cardiovascular event in 15% of subjects (63 out of 420 participants),57 and a 2025 meta-analysis determined that long-term supplementation with doses as low as 100mg significantly reduced users systolic blood pressure.58 IM8 has perhaps too little CoQ10 to make a noticeable difference in, say, heart attack risk, but it seems well-dosed for people looking to alleviate hypertension
In clinical practice, the addition of BPC-157 has been associated with improved rather than worsened GI tolerance, consistent with BPC-157's known gastroprotective pharmacology
When bile stalls, toxins are reabsorbed
Both phases contain nutrients ensuring cell development
doi: 10.1038/s41423-020-0365-3 62 RobinsonGAWilkinsonMGLWincupC